weight loss drugs

A new study reports that about one in six children taking GLP-1 medications, such as Ozempic and Wegovy, developed nutritional deficiencies while on the drugs. The findings raise concerns that appetite suppression and reduced intake may leave some children short on key nutrients, prompting calls for closer monitoring of children prescribed these increasingly used weight-loss medications.

Zepbound and Mounjaro, the popular tirzepatide weight-loss and diabetes drugs from Eli Lilly, may do more than curb appetite. New research suggests they could also switch on the body's brown fat, a tissue that burns calories to generate heat. If confirmed, the finding could help explain part of the drugs' effectiveness and open new angles for obesity treatment research.

Health experts say weight loss drugs could also help treat women's reproductive health issues, according to reporting picked up by US local broadcaster WCAX. The claim ties a growing class of medications already used for obesity to potential benefits in gynaecological care. No further details on specific conditions, drugs or clinical evidence were provided in the coverage.

A new study has connected the use of GLP-1 weight-loss and diabetes medications in children with nutritional deficiencies, according to Scripps News, which published an interactive report on the findings. The drugs, widely prescribed to minors amid rising childhood obesity rates, may leave young users short of key nutrients. The findings add to ongoing debate over the safety and supervision of GLP-1 treatment in pediatric patients.